Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference.
Kornbluth
A
A
Mt. Sinai Medical Center, New York, New York 10128, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000188:drug therapy*; D017277:Drug Approval; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D000069285:Infliximab